Walking the Hemostatic Tightrope in Stroke, VTE, and Orthopedic Surgery: A Scoping Review
SN Comprehensive Clinical Medicine · 29.10.2026 · 8 (1)
DOI: 10.1007/s42399-026-02840-8 ↗Kurz gefasst
Scoping Review in der Zeitschrift SN Comprehensive Clinical Medicine, online erschienen am 29.10.2026. Verfasst von Samer G. Salman und 5 weiteren Autor:innen. Die Arbeit nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Schlaganfall
Abstract (Originalsprache)
Background
Patients with prior stroke undergoing orthopedic surgery face elevated risks of recurrent stroke and venous thromboembolism, while thromboprophylaxis must be balanced against hemorrhage. Evidence is fragmented across subspecialties.
Objectives
To map the epidemiology, risk stratification, timing, anesthesia and thromboprophylaxis evidence for this population, labeling each recommendation by evidence type.
Methods
Following PRISMA-ScR and Joanna Briggs Institute guidance, we searched PubMed, Embase and the Cochrane Library from inception through December 2025, with supplementary identification to the final search date of 23 January 2026. No protocol was registered, 76 sources met inclusion criteria, and formal critical appraisal was not undertaken.
Results
Deferring elective arthroplasty at least 3 months after stroke is reasonable, but 3 to 6 months is individualized rather than optimal, derived largely from noncardiac surgery; one arthroplasty cohort suggests longer. Hip fracture surgery should proceed within 24 to 48 h after ischemic or remote hemorrhagic stroke; after recent hemorrhagic stroke timing is unestablished, with no fixed delay supported because delay is itself harmful. Mortality advantages of neuraxial anesthesia are observational, randomized trials including REGAIN are null, and technique is individualized. No randomized trial has compared prophylactic agents here, so preferring low-molecular-weight heparin or a direct oral anticoagulant over aspirin is extrapolation, not established standard. Factor XIa inhibition remains investigational: phase 2 trials with venographic endpoints that largely excluded patients with stroke.
Conclusions
Management requires individualized, multidisciplinary assessment, not uniform rules; most positions rest on indirect or inferential evidence. Only 8 of 76 charted sources report stroke subtype or the interval since stroke.
Zitieren
APA
Salman, S. G., Phadke, R. A., Nair, A., Kumar, R., Momin, A., & Tavakkoli, A. (2026). Walking the Hemostatic Tightrope in Stroke, VTE, and Orthopedic Surgery: A Scoping Review. SN Comprehensive Clinical Medicine, 8(1). https://doi.org/10.1007/s42399-026-02840-8
Vancouver
Salman SG, Phadke RA, Nair A, Kumar R, Momin A, Tavakkoli A. Walking the Hemostatic Tightrope in Stroke, VTE, and Orthopedic Surgery: A Scoping Review. SN Comprehensive Clinical Medicine. 2026;8(1). doi:10.1007/s42399-026-02840-8
BibTeX
@article{Salman2026,
author = {Salman, Samer G. and Phadke, Rohan A. and Nair, Adithya and Kumar, Rahul and Momin, Arbaz and Tavakkoli, Alireza},
title = {Walking the Hemostatic Tightrope in Stroke, VTE, and Orthopedic Surgery: A Scoping Review},
journal = {SN Comprehensive Clinical Medicine},
year = {2026},
volume = {8},
number = {1},
doi = {10.1007/s42399-026-02840-8}
}
EUVIMED